title: Fibrosis in Hodgkin and non-Hodgkin lymphomas.
abstract: There is little quantitative information about the amount of fibrosis in lymphomas. The aim of the present study was to investigate the amount of fibrosis in lymphomas and to highlight the relationship between fibrosis and mast cells, the key players of fibrosis. Tissue sections of 60 patients with diagnosis of lymphoma were reevaluated for classification. The mean fibrotic-stained area percentage (F-SAP) was determined in van Gieson-stained digital images using image analysis (Mediscope, Dokuz Eylul University, Clinical Engineering, Turkey). Mast cells were visualized using streptavidin peroxidase immunohistochemistry with anti-tryptase staining. Twenty-seven (44%) cases were Hodgkin's lymphoma (HL). F-SAP was 11.09+/-8.96 and 1.72+/-1.76 for HL and non-HL cases (Mann-Whitney U, p<0.000), and the mean mast cell count (MMCC) was 24.63+/-13.58 and 8.03+/-8.07, respectively (Mann-Whitney U test, p<0.000). There was a significant difference between F-SAP and MMCC concerning different types of lymphomas (Kruskal-Wallis test, p>0.000). F-SAP was highest in nodular sclerosis HL, and MMCC was highest in mixed cellular HL. There was a strong positive correlation between MMCC and F-SAP (Pearson Correlation test, p<0.000, r=0.51). These results suggest that the amount of fibrosis demonstrates differences in subtypes of lymphomas, and mast cells are increased in fibrosing lymphomas. However, it seems likely that more than one cell type is involved.
authors.affiliation: Department of Pathology, Adnan Menderes University School of Medicine, 09100 Aydin, Turkey. cantent@yahoo.com
authors.forename: Canten
authors.initials: C
authors.lastname: Tataroglu
authors.forename: Sülen
authors.initials: S
authors.lastname: Sarioglu
authors.forename: Aydanur
authors.initials: A
authors.lastname: Kargi
authors.forename: Sermin
authors.initials: S
authors.lastname: Ozkal
authors.forename: Ozlem
authors.initials: O
authors.lastname: Aydin
mesh_terms: D005355:Fibrosis; D006689:Hodgkin Disease / Q000201:enzymology / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000473:pathology; D008224:Lymphoma, Follicular / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000201:enzymology / Q000473:pathology*; D008407:Mast Cells / Q000201:enzymology / Q000473:pathology*; D012720:Severity of Illness Index; D012815:Signal Processing, Computer-Assisted; D013194:Staining and Labeling / Q000379:methods; D053802:Tryptases / Q000032:analysis